Cure My Disease

Don't miss your cure!

 Log in / Sign up

New breast cancer trial adapts treatment based on early response

NCT ID NCT07340398

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is for people with HER2-positive early breast cancer. After initial standard therapy, those who don't respond well will switch to a stronger combination of newer drugs, including trastuzumab-rezetecan and pyrotinib. The goal is to see if this personalized approach can eliminate more cancer before surgery and reduce side effects. About 200 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Trastuzumab-rezetecan (SHR-A1811), pertuzumab, nab-paclitaxel, carboplatin, trastuzumab, pyrotinib
What this could lead to
If successful, this could offer a more effective treatment option for people with HER2-positive early breast cancer who don't respond well to standard therapy, potentially increasing the chance of eliminating the cancer before surgery.
What could go wrong
This is a small, early-phase (Phase 2) study, so results may not apply to everyone. The new drug combination may cause side effects or not improve outcomes compared to existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE EARLY BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.